The global biologics market, projected to grow from roughly USD 355 billion in 2025 to USD 582 billion by 2030, is entering an era defined by complexity. While monoclonal antibodies still dominate, new modalities—such as antibody-drug conjugates (ADCs), bispecific and multispecific antibodies, fusion proteins, and recombinant constructs—are rising rapidly, expected to account for 35 percent … The Biologics Landscape Is Changing—Fast: CDMOs Race to Integrate Development, Scale, and Next-Gen Modalities Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.